Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

Applied Clinical Education

Emerging Immunotherapies in Bladder Cancer: PD-1, PD-LI, and CTLA-4 Inhibitors

Access Activity

Overview / Abstract:

Goal:
The goal of this educational activity is to improve clinicians’ abilities to diagnose and treat bladder cancer appropriately, with particular emphasis on emerging therapies such as PD-1, PD-L1, and CTLA-4 inhibitors.

Learning Objectives:
At the completion of this activity, participants should be better able to:

1. Discuss the pathophysiology of bladder cancer, including the role of the PD-1, PD-L1, and CTLA-4 pathways.

2. Explain the diagnosis and staging of bladder cancer.

3. Describe current treatments for bladder cancer.

4. Identify the potential of emerging immunotherapies for bladder cancer, such as PD-1, PD-L1, and CTLA-4

Expiration

Nov 01, 2017

Discipline(s)

Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME, Radiology / RAD Tech CE

Format

Monograph, Online

Credits / Hours

1.0 AMA PRA Category 1 Credit™

Accreditation

ACCME

Presenters / Authors / Faculty

Co-Chairs:

Walter M Stadler, MD
Fred C. Buffett Professor of Medicine
and Surgery
Chief, Section of Hematology/Oncology
Deputy Director, University of Chicago
Comprehensive Cancer Center
University of Chicago Medicine
Chicago, Illinois

Daniel P Petrylak, MD
Professor of Medicine (Medical Oncology)
and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational
Research Group
Yale Cancer Center
New Haven, Connecticut

Activity Specialities / Related Topics

Immunology / Immunosuppression, Oncology / Cancer / Radiation Therapy, Other, Pain Management, Pathology, Pharmacology, Radiology / Imagery / Nuclear Medicine

Sponsors / Supporters / Grant Providers

This activity is supported by an educational grant from Bristol-Myers Squibb, Genentech, and Merck & Co.

Keywords / Search Terms

Applied Clinical Education diagnose and treat bladder cancer appropriately, with particular emphasis on emerging therapies such as PD-1, PD-L1, CTLA-4 inhibitors, diagnosis of bladder cancer, staging of bladder cancer, emerging immunotherapies, oncology health care professionals who treat patients with bladder cancer, oncologists, hematologist/oncologists, radiation oncologists, urologists, oncology nurses, pharmacists Free CE CME

Access Activity

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.